


Velozell Revenue
Biotechnology Research • Amsterdam, North Holland, Netherlands • 1-10 Employees
Velozell revenue & valuation
| Annual revenue | $85,555 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $273,776 |
| Total funding | No funding |
Key Contact at Velozell
Felix Kasper
Consultant (Founder)
Company overview
| Headquarters | Amsterdam, North Holland, Netherlands |
| NAICS | 541714 |
| Keywords | CMC, Process Simplification, Quality By Design, Tech Transfer, Cell And Gene Therapy, Msat, Process Characterization, Single-Use Bioreactor, Bioreactor Design, Bioreactor Strategy, Organization Scale-Up |
| Founded | 2019 |
| Employees | 1-10 |
About Velozell
Velozell helps biotech, CDMOs, and tool vendors turn early-stage bioprocess ideas into GMP-ready, adoptable solutions. We’re bioreactor-fluent—wave, STR (HT to 2,000 L), and adherent fixed-bed—with deep MSAT/CMC experience across cell & gene therapy, vectors, and RNA. We design QbD/DoE studies, execute tech transfer, align documentation for IND/IMPD/BLA/MAA, and package capabilities into clear, scalable offerings. What we deliver: reliable scale-up/transfer, lower deviation rates, faster time-to-run, and product decisions grounded in operator reality. Focus areas: Bioreactor strategy & scale-up • Tech transfer & lifecycle validation • QbD/DoE & comparability • MSAT/CMC readiness • Digital foundations (CRM/CMMS/ERP) • CGT vector & cell expansion
Employees by Management Level
Total employees: 1-10
Seniority
Employees
Funding Data
Velozell has never raised funding before.
Frequently asked questions
4.8
40,000 users



